GlaxoSmithKline has confirmed nine new government contracts for a further 96 million doses of its pandemic (H1N1) 2009 adjuvanted influenza vaccine since 22 July 2009.
The new orders bring the total number of doses ordered for GSK's adjuvanted vaccine to 291 million. The vaccine will first become available from September this year, with further shipments expected in the second half of 2009 and early 2010.
While exact details of which countries have ordered the vaccine are not available, GSK has made it clear that at least 20% of production at the company's Canadian manufacturing site will be allocated to developing nations.
Included within this percentage are the 50 million doses that GSK has declared it will donate to the World Health Organisation.
GSK will also ensure that the vaccine is affordable by operating a tiered-pricing policy based on World Bank classification of countries and Global Alliance for Vaccines and Immunisation eligibility.
Once ready the GSK vaccine will consist of an antigen of the recently isolated pandemic H1N1 2009 influenza strain combined with GSK's proprietary adjuvant system AS03.
The adjuvant system helps to increase the number of vaccine doses that can be produced by stimulating a higher immune response while using a smaller amount of antigen.